Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 864-870

  George, Suzanne ^a   Desai, Jayesh ^a   Paul Eder, J ^a   Manola, Judith ^a   Ryan, David P ^a   Appleman, Leonard J ^a   Demetri, George D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Clinical trial; Kinase inhibition; Targeted therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR; IMATINIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN TOXICITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DESMOID TUMOR; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LEIOMYOSARCOMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 33745292308     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.010     Document Type: Article

References (47)

1. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4 (1998) 655-657
2. Rodt S.A., Ahlen K., Berg A., et al. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495 (1996) 193-200
3. Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumours. Cancer Res 61 (2001) 2929-2934
4. Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signalling in tumour stroma enhances antitumour effect of chemotherapy. Cancer Res 62 (2002) 5476-5484
5. Fudge K., Bostwick D.G., and Stearns M.E. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 29 (1996) 282-286
6. Uehara H., Kim S.J., Karashima T., et al. Effects of blocking platelet-derived growth factor-receptor signalling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95 (2003) 458-470
7. Antoniades H.N., Galanopoulos T., Neville-Golden J., et al. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci U S A 89 (1992) 3942-3946
8. Yi B., Williams P.J., Niewolna M., et al. Tumour-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62 (2002) 917-923
9. Wang J., Coltrera M.D., and Gown A.M. Cell proliferation in human soft tissue tumours correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Cancer Res 54 (1994) 560-564
10. Hermansson M., Nister M., Betsholtz C., et al. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 85 (1988) 7748-7752
11. Nister M., Libermann T.A., Betsholtz C., et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48 (1988) 3910-3918
12. Mauro A., Bulfone A., Turco E., et al. Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas. Childs Nerv Syst 7 (1991) 432-436
13. Apte S.M., Bucana C.D., Killion J.J., et al. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 93 (2004) 78-86
14. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56 (1996) 100-104
15. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
16. Okuda K., Weisberg E., Gilliland D.G., et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 97 (2001) 2440-2448
17. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 344 (2001) 1031-1037
18. Kantarjian H., Sawyers C., Hochhaus A., et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 346 (2002) 645-652
19. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 348 (2003) 994-1004
20. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 347 (2002) 472-480
21. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
22. Sjoblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumours by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61 (2001) 5778-5783
23. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100 (2002) 623-626
24. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20 (2002) 3586-3591
25. Gotlib J., Cools J., Malone III J.M., et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891 [Epub 2003 Nov 20]
26. Carroll M., Tomasson M.H., Barker G.F., et al. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukaemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signalling pathways. Proc Natl Acad Sci U S A 93 (1996) 14845-14850
27. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 (2002) 481-487
28. Magnusson M.K., Meade K.E., Nakamura R., et al. Activity of STI571 in chronic myelomonocytic leukaemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100 (2002) 1088-1091
29. Tipping A.J., Mahon F.X., Zafirides G., et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukaemia 16 (2002) 2349-2357
30. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96 (2000) 3195-3199
31. Hwang R.F., Yokoi K., Bucana C.D., et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9 (2003) 6534-6544
32. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
33. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
34. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13 (1995) 1537-1545
35. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 (1993) 1269-1275
36. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
37. Anderson H., Hopwood P., Stephens R.J., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83 (2000) 447-453
38. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270-3275
39. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
40. Bramwell V.H., Morris D., Ernst D.S., et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 8 (2002) 383-393
41. Minderman H., O'Loughlin K.L., Pendyala L., et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10 (2004) 1826-1834
42. Bahrani A., Hwang S., Malik K., et al. Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractoty solid tumours. ASCO Annual Meeting Proceedings. J Clin Oncol 22 (2004) 3087
43. Thompson D.S., Hainsworth J.D., Spigel D.R., et al. Irinotecan carboplatin and imatinib in the first line treatment of extensive stage small cell lung cancer: a phase II study of the Minnie Pearl Cancer Research Network. Proc Amer Soc Clin Oncol 23 (2005) [Abstract 7049]
44. Schuter L., Flaherty K., Davidson R., et al. A phase I trial of imatinib and temozolamide in patients with metastatic melanoma. Proc Amer Soc Clin Oncol 23 (2004) 724 [Abstract 7572]
45. Poplin E., Gharibo M., Rodriguez L., et al. Phase I study of imatinib mesylate and gemcitabine in patients with refractory solid tumour malignancy. Proc Amer Soc Clin Oncol 24 (2005) 40 [Abstract 3100]
46. Sathornsumetee S., Reardon D.A., Quinn J., et al. A phase I dose escalation study of imatinib mesylate plus standard dose temozolamide in patients with malignant glioma. J Clin Oncol 23 16 suppl;pt 1 (2005) 124s [Abstract 1540]
47. Malik S.M., Moore D.J., Hwang J.J., et al. Pulse dose imatinid and weekly paclitaxel phase I trial for advanced refractory tumours. Proc Soc Amer Clin Oncol 24 (2005) 43 [Abstract 3118]